| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.796 | 0.003 | 0.932 | Non-steroidal antiinflammatory agent | 0.759 0.003 DBMET00156 0.932 0.002 DBMET00157 0.439 0.01 DBMET00158 0.408 0.013 DBMET01351 | DBMET00157 | |
| 0.67 | 0.002 | 0.838 | Cyclooxygenase 3 inhibitor | 0.662 0.002 DBMET00156 0.838 0.001 DBMET00157 0.278 0.007 DBMET00158 0.27 0.007 DBMET01351 | DBMET00157 | |
| 0.589 | 0.004 | 0.619 | Prostaglandin antagonist | 0.619 0.003 DBMET00156 0.14 0.011 DBMET00157 0.434 0.004 DBMET00158 0.454 0.004 DBMET01351 | DBMET00156 | |
| 0.557 | 0.004 | 0.58 | NADPH oxidase inhibitor | 0.58 0.004 DBMET00156 0.49 0.004 DBMET00157 0.345 0.008 DBMET00158 0.361 0.006 DBMET01351 | DBMET00156 | |
| 0.603 | 0.053 | 0.786 | Antiinflammatory | 0.664 0.038 DBMET00156 0.786 0.017 DBMET00157 0.406 0.136 DBMET00158 0.496 0.089 DBMET01351 | DBMET00157 | |
| 0.479 | 0.003 | 0.501 | Prostaglandin D2 antagonist | 0.501 0.003 DBMET00156 0.047 0.007 DBMET00157 0.307 0.003 DBMET00158 0.322 0.003 DBMET01351 | DBMET00156 | |
| 0.464 | 0.005 | 0.506 | Cyclooxygenase 1 inhibitor | 0.506 0.005 DBMET00156 0.351 0.01 DBMET00157 0.282 0.016 DBMET00158 0.313 0.013 DBMET01351 | DBMET00156 | |
| 0.486 | 0.036 | 0.486 | Thyroid hormone antagonist | 0.448 0.043 DBMET00156 0.423 0.049 DBMET00158 0.388 0.059 DBMET01351 | ||
| 0.451 | 0.005 | 0.469 | Cyclooxygenase inhibitor | 0.469 0.005 DBMET00156 0.36 0.01 DBMET00157 0.292 0.019 DBMET00158 0.306 0.016 DBMET01351 | DBMET00156 | |
| 0.467 | 0.038 | 0.467 | Thyroid hormone beta antagonist | 0.418 0.048 DBMET00156 0.389 0.057 DBMET00158 0.343 0.071 DBMET01351 | ||
| 0.434 | 0.013 | 0.462 | Anesthetic general | 0.462 0.01 DBMET00156 0.377 0.019 DBMET00157 0.308 0.031 DBMET00158 0.339 0.026 DBMET01351 | DBMET00156 | |
| 0.423 | 0.014 | 0.474 | Cyclic AMP phosphodiesterase inhibitor | 0.42 0.014 DBMET00156 0.43 0.013 DBMET00157 0.474 0.008 DBMET00158 0.471 0.009 DBMET01351 | DBMET00158 | |
| 0.406 | 0.006 | 0.406 | Insulin sensitizer | 0.402 0.006 DBMET00156 0.252 0.033 DBMET00157 0.292 0.018 DBMET00158 0.29 0.018 DBMET01351 | ||
| 0.4 | 0.004 | 0.43 | Prostaglandin EP2 antagonist | 0.43 0.004 DBMET00156 0.218 0.005 DBMET00157 0.31 0.004 DBMET00158 0.334 0.004 DBMET01351 | DBMET00156 | |
| 0.389 | 0.005 | 0.407 | Phospholipase A2 inhibitor | 0.407 0.005 DBMET00156 0.311 0.012 DBMET00157 0.275 0.018 DBMET00158 0.292 0.015 DBMET01351 | DBMET00156 | |
| 0.384 | 0.004 | 0.501 | Histidine decarboxylase inhibitor | 0.501 0.003 DBMET00156 0.342 0.005 DBMET00158 0.462 0.003 DBMET01351 | DBMET00156 | |
| 0.378 | 0.007 | 0.388 | Cyclooxygenase 2 inhibitor | 0.388 0.006 DBMET00156 0.305 0.013 DBMET00157 0.23 0.024 DBMET00158 0.238 0.022 DBMET01351 | DBMET00156 | |
| 0.374 | 0.035 | 0.495 | Calcium channel activator | 0.329 0.065 DBMET00156 0.495 0.005 DBMET00158 0.459 0.009 DBMET01351 | DBMET00158 | |
| 0.373 | 0.044 | 0.401 | Lipoxygenase inhibitor | 0.401 0.037 DBMET00156 0.36 0.048 DBMET00158 0.389 0.04 DBMET01351 | DBMET00156 | |
| 0.379 | 0.055 | 0.627 | Antithrombotic | 0.417 0.045 DBMET00156 0.627 0.014 DBMET00157 0.427 0.043 DBMET00158 0.462 0.035 DBMET01351 | DBMET00157 | |
| 0.388 | 0.065 | 0.406 | Toll-Like receptor 7 agonist | 0.406 0.058 DBMET00156 0.342 0.086 DBMET00158 0.362 0.076 DBMET01351 | DBMET00156 | |
| 0.385 | 0.067 | 0.402 | Toll-Like receptor agonist | 0.402 0.059 DBMET00156 0.343 0.086 DBMET00158 0.363 0.076 DBMET01351 | DBMET00156 | |
| 0.371 | 0.108 | 0.601 | Cyclophilin D inhibitor | 0.414 0.084 DBMET00156 0.601 0.027 DBMET00157 0.356 0.118 DBMET00158 0.409 0.086 DBMET01351 | DBMET00157 | |
| 0.308 | 0.072 | 0.397 | Sodium/bile acid cotransporter inhibitor | 0.336 0.049 DBMET00156 0.375 0.026 DBMET00158 0.397 0.018 DBMET01351 | DBMET01351 | |
| 0.233 | 0.003 | 0.247 | 1-Alkyl-2-acetylglycerophosphocholine esterase inhibitor | 0.247 0.003 DBMET00156 0.05 0.009 DBMET00158 0.053 0.008 DBMET01351 | DBMET00156 | |
| 0.228 | 0.004 | 0.228 | Peroxisome proliferator-activated receptor gamma antagonist | 0.174 0.005 DBMET00156 0.078 0.036 DBMET00157 0.108 0.012 DBMET00158 0.094 0.019 DBMET01351 | ||
| 0.296 | 0.076 | 0.427 | Interleukin 2 agonist | 0.349 0.046 DBMET00156 0.427 0.02 DBMET00157 0.326 0.057 DBMET00158 0.387 0.031 DBMET01351 | DBMET00157 | |
| 0.265 | 0.046 | 0.484 | Platelet aggregation inhibitor | 0.195 0.084 DBMET00156 0.484 0.01 DBMET00158 0.414 0.017 DBMET01351 | DBMET00158 | |
| 0.28 | 0.076 | 0.28 | Hypoxia-inducible factor 1 alpha inhibitor | 0.28 0.076 DBMET00156 0.25 0.1 DBMET00157 0.239 0.111 DBMET00158 0.238 0.111 DBMET01351 | ||
| 0.295 | 0.097 | 0.706 | Transcription factor NF kappa B inhibitor | 0.346 0.078 DBMET00156 0.706 0.02 DBMET00157 0.325 0.084 DBMET00158 0.378 0.069 DBMET01351 | DBMET00157 | |
| 0.226 | 0.032 | 0.233 | Succinate dehydrogenase inhibitor | 0.233 0.029 DBMET00156 0.216 0.037 DBMET00158 0.224 0.033 DBMET01351 | DBMET00156 | |
| 0.232 | 0.042 | 0.277 | Mcl-1 antagonist | 0.277 0.027 DBMET00156 0.123 0.121 DBMET00157 0.216 0.048 DBMET00158 0.272 0.029 DBMET01351 | DBMET00156 | |
| 0.192 | 0.006 | 0.192 | Amidase inhibitor | 0.192 0.006 DBMET00156 | ||
| 0.258 | 0.072 | 0.466 | Hypoglycemic | 0.279 0.061 DBMET00156 0.466 0.019 DBMET00157 0.251 0.076 DBMET00158 0.277 0.062 DBMET01351 | DBMET00157 | |
| 0.221 | 0.037 | 0.394 | Amylase inhibitor | 0.257 0.026 DBMET00156 0.394 0.009 DBMET00157 0.292 0.019 DBMET00158 0.342 0.014 DBMET01351 | DBMET00157 | |
| 0.255 | 0.074 | 0.305 | Gastrin inhibitor | 0.254 0.075 DBMET00156 0.305 0.03 DBMET00158 0.304 0.03 DBMET01351 | DBMET00158 | |
| 0.192 | 0.015 | 0.258 | Interleukin 8 antagonist | 0.258 0.005 DBMET00156 0.179 0.019 DBMET00158 0.238 0.007 DBMET01351 | DBMET00156 | |
| 0.211 | 0.04 | 0.294 | Diuretic | 0.294 0.023 DBMET00156 0.181 0.053 DBMET00157 0.151 0.077 DBMET00158 0.2 0.044 DBMET01351 | DBMET00156 | |
| 0.168 | 0.007 | 0.174 | Prostaglandin E2 antagonist | 0.174 0.007 DBMET00156 0.073 0.022 DBMET00158 0.072 0.023 DBMET01351 | DBMET00156 | |
| 0.169 | 0.009 | 0.169 | Peroxisome proliferator-activated receptor gamma agonist | 0.164 0.01 DBMET00156 0.084 0.038 DBMET00157 0.139 0.015 DBMET00158 0.128 0.018 DBMET01351 | ||
| 0.163 | 0.007 | 0.179 | Cannabinoid CB2 receptor antagonist | 0.179 0.006 DBMET00156 | DBMET00156 | |
| 0.308 | 0.156 | 0.521 | 5 Hydroxytryptamine release inhibitor | 0.326 0.138 DBMET00156 0.261 0.213 DBMET00157 0.503 0.032 DBMET00158 0.521 0.026 DBMET01351 | DBMET01351 | |
| 0.176 | 0.031 | 0.238 | Cystathionine beta-synthase inhibitor | 0.238 0.017 DBMET00156 0.093 0.085 DBMET00157 0.158 0.037 DBMET00158 0.217 0.021 DBMET01351 | DBMET00156 | |
| 0.227 | 0.083 | 0.365 | Antiamyloidogenic | 0.223 0.084 DBMET00156 0.365 0.036 DBMET00157 0.209 0.093 DBMET00158 0.206 0.095 DBMET01351 | DBMET00157 | |
| 0.187 | 0.046 | 0.221 | Arachidonic acid antagonist | 0.2 0.033 DBMET00156 0.211 0.023 DBMET00158 0.221 0.016 DBMET01351 | DBMET01351 | |
| 0.297 | 0.16 | 0.616 | Calcium channel L-type activator | 0.37 0.103 DBMET00156 0.588 0.007 DBMET00158 0.616 0.005 DBMET01351 | DBMET01351 | |
| 0.21 | 0.075 | 0.354 | Psychostimulant | 0.222 0.069 DBMET00156 0.34 0.034 DBMET00158 0.354 0.031 DBMET01351 | DBMET01351 | |
| 0.286 | 0.153 | 0.39 | Analgesic | 0.39 0.089 DBMET00156 | DBMET00156 | |
| 0.144 | 0.016 | 0.155 | Cannabinoid receptor antagonist | 0.155 0.014 DBMET00156 | DBMET00156 | |
| 0.266 | 0.144 | 0.562 | Histamine release inhibitor | 0.347 0.101 DBMET00156 0.293 0.127 DBMET00157 0.516 0.024 DBMET00158 0.562 0.014 DBMET01351 | DBMET01351 | |
| 0.233 | 0.114 | 0.336 | Insulysin inhibitor | 0.298 0.06 DBMET00156 0.28 0.071 DBMET00158 0.336 0.04 DBMET01351 | DBMET01351 | |
| 0.148 | 0.038 | 0.183 | 5-Lipoxygenase inhibitor | 0.183 0.028 DBMET00156 0.131 0.045 DBMET00158 0.168 0.032 DBMET01351 | DBMET00156 | |
| 0.206 | 0.097 | 0.332 | Platelet antagonist | 0.214 0.092 DBMET00156 0.268 0.065 DBMET00157 0.314 0.048 DBMET00158 0.332 0.043 DBMET01351 | DBMET01351 | |
| 0.122 | 0.016 | 0.147 | Sphingosine 1-phosphate receptor 4 agonist | 0.133 0.012 DBMET00156 0.135 0.012 DBMET00158 0.147 0.009 DBMET01351 | DBMET01351 | |
| 0.137 | 0.032 | 0.222 | Potassium channel (Ca-activated) activator | 0.191 0.016 DBMET00156 0.169 0.022 DBMET00158 0.222 0.011 DBMET01351 | DBMET01351 | |
| 0.119 | 0.014 | 0.159 | Aldose reductase inhibitor | 0.159 0.01 DBMET00156 0.076 0.025 DBMET00157 0.095 0.019 DBMET00158 0.139 0.012 DBMET01351 | DBMET00156 | |
| 0.206 | 0.102 | 0.566 | Aldehyde oxidase inhibitor | 0.292 0.068 DBMET00156 0.46 0.038 DBMET00158 0.566 0.024 DBMET01351 | DBMET01351 | |
| 0.111 | 0.01 | 0.16 | GABA B receptor agonist | 0.126 0.006 DBMET00156 0.138 0.005 DBMET00158 0.16 0.004 DBMET01351 | DBMET01351 | |
| 0.135 | 0.034 | 0.195 | Multidrug resistance-associated protein 1 inhibitor | 0.128 0.04 DBMET00156 0.195 0.012 DBMET00157 0.1 0.078 DBMET00158 | DBMET00157 | |
| 0.284 | 0.184 | 0.588 | Apoptosis agonist | 0.295 0.176 DBMET00156 0.588 0.052 DBMET00157 0.344 0.142 DBMET00158 0.362 0.132 DBMET01351 | DBMET00157 | |
| 0.119 | 0.021 | 0.141 | Bile acid receptor antagonist | 0.13 0.013 DBMET00156 0.127 0.015 DBMET00158 0.141 0.009 DBMET01351 | DBMET01351 | |
| 0.296 | 0.198 | 0.517 | Caspase 9 stimulant | 0.262 0.239 DBMET00156 0.387 0.119 DBMET00157 0.517 0.054 DBMET00158 0.476 0.07 DBMET01351 | DBMET00158 | |
| 0.135 | 0.037 | 0.141 | Sphingosine 1-phosphate receptor 2 agonist | 0.141 0.032 DBMET00156 | DBMET00156 | |
| 0.139 | 0.045 | 0.139 | Sphingosine 1-phosphate receptor 4 antagonist | 0.132 0.053 DBMET00156 0.112 0.09 DBMET00158 0.106 0.103 DBMET01351 | ||
| 0.166 | 0.073 | 0.244 | Catenin beta inhibitor | 0.182 0.05 DBMET00156 0.219 0.021 DBMET00158 0.244 0.012 DBMET01351 | DBMET01351 | |
| 0.231 | 0.139 | 0.397 | Cholesterol antagonist | 0.262 0.117 DBMET00156 0.397 0.05 DBMET00157 0.309 0.085 DBMET00158 0.337 0.07 DBMET01351 | DBMET00157 | |
| 0.095 | 0.007 | 0.095 | Calcium channel P-type blocker | 0.062 0.052 DBMET00156 0.064 0.042 DBMET00158 | ||
| 0.166 | 0.078 | 0.166 | 3C-like protease (Human coronavirus) inhibitor | 0.142 0.115 DBMET00156 0.155 0.093 DBMET00158 | ||
| 0.102 | 0.016 | 0.122 | Cannabinoid CB1 receptor antagonist | 0.122 0.011 DBMET00156 | DBMET00156 | |
| 0.132 | 0.046 | 0.203 | TRPA1 agonist | 0.153 0.029 DBMET00156 0.177 0.017 DBMET00158 0.203 0.01 DBMET01351 | DBMET01351 | |
| 0.203 | 0.118 | 0.284 | Interleukin agonist | 0.239 0.087 DBMET00156 0.28 0.059 DBMET00157 0.251 0.078 DBMET00158 0.284 0.056 DBMET01351 | DBMET01351 | |
| 0.106 | 0.023 | 0.111 | Leukotriene synthesis inhibitor | 0.111 0.02 DBMET00156 0.073 0.042 DBMET00158 0.078 0.038 DBMET01351 | DBMET00156 | |
| 0.123 | 0.042 | 0.263 | DOPA decarboxylase inhibitor | 0.184 0.009 DBMET00156 0.179 0.01 DBMET00158 0.263 0.003 DBMET01351 | DBMET01351 | |
| 0.111 | 0.029 | 0.135 | Cathepsin G inhibitor | 0.135 0.024 DBMET00156 0.074 0.049 DBMET01351 | DBMET00156 | |
| 0.142 | 0.062 | 0.194 | Tubulin antagonist | 0.194 0.039 DBMET00158 0.114 0.085 DBMET01351 | DBMET00158 | |
| 0.177 | 0.098 | 0.373 | Interleukin antagonist | 0.239 0.066 DBMET00156 0.279 0.053 DBMET00158 0.373 0.035 DBMET01351 | DBMET01351 | |
| 0.132 | 0.055 | 0.165 | Cholesterol synthesis inhibitor | 0.146 0.046 DBMET00156 0.15 0.045 DBMET00158 0.165 0.037 DBMET01351 | DBMET01351 | |
| 0.209 | 0.135 | 0.28 | 5 Hydroxytryptamine uptake stimulant | 0.229 0.105 DBMET00156 0.254 0.077 DBMET00158 0.28 0.056 DBMET01351 | DBMET01351 | |
| 0.097 | 0.023 | 0.097 | Leukotriene antagonist | 0.093 0.025 DBMET00156 0.057 0.054 DBMET00157 0.094 0.024 DBMET00158 0.09 0.026 DBMET01351 | ||
| 0.239 | 0.167 | 0.265 | Antiobesity | 0.265 0.144 DBMET00156 | DBMET00156 | |
| 0.075 | 0.009 | 0.075 | Carnitine palmitoyltransferase 1B inhibitor | 0.064 0.015 DBMET00156 0.075 0.009 DBMET00158 0.061 0.017 DBMET01351 | ||
| 0.12 | 0.054 | 0.149 | Mucolytic | 0.111 0.063 DBMET00156 0.112 0.062 DBMET00157 0.149 0.033 DBMET00158 0.14 0.039 DBMET01351 | DBMET00158 | |
| 0.076 | 0.013 | 0.079 | DNA helicase inhibitor | 0.077 0.013 DBMET00156 0.078 0.012 DBMET00158 0.079 0.011 DBMET01351 | DBMET01351 | |
| 0.134 | 0.075 | 0.159 | Farnesoid X receptor antagonist | 0.159 0.043 DBMET00156 0.125 0.092 DBMET00158 0.154 0.047 DBMET01351 | DBMET00156 | |
| 0.188 | 0.132 | 0.544 | 5 Hydroxytryptamine release stimulant | 0.21 0.113 DBMET00156 0.508 0.026 DBMET00158 0.544 0.021 DBMET01351 | DBMET01351 | |
| 0.103 | 0.047 | 0.121 | ABCA1 expression enhancer | 0.104 0.045 DBMET00156 0.118 0.032 DBMET00158 0.121 0.03 DBMET01351 | DBMET01351 | |
| 0.154 | 0.099 | 0.202 | Phospholipase C inhibitor | 0.202 0.043 DBMET00156 0.146 0.114 DBMET00158 0.191 0.05 DBMET01351 | DBMET00156 | |
| 0.069 | 0.015 | 0.078 | Leukotriene C antagonist | 0.076 0.01 DBMET00156 0.071 0.013 DBMET00158 0.078 0.009 DBMET01351 | DBMET01351 | |
| 0.075 | 0.023 | 0.091 | Thromboxane antagonist | 0.091 0.014 DBMET00156 0.051 0.04 DBMET00158 0.071 0.025 DBMET01351 | DBMET00156 | |
| 0.072 | 0.021 | 0.075 | Peroxisome proliferator-activated receptor alpha agonist | 0.042 0.039 DBMET00156 0.075 0.019 DBMET00158 0.045 0.037 DBMET01351 | DBMET00158 | |
| 0.151 | 0.1 | 0.212 | Neurotensin receptor agonist | 0.169 0.064 DBMET00156 0.189 0.042 DBMET00158 0.212 0.029 DBMET01351 | DBMET01351 | |
| 0.081 | 0.031 | 0.096 | Bcl2 antagonist | 0.096 0.02 DBMET00156 | DBMET00156 | |
| 0.169 | 0.119 | 0.191 | Hypolipemic | 0.18 0.109 DBMET00156 0.191 0.101 DBMET00157 0.17 0.118 DBMET00158 0.185 0.106 DBMET01351 | DBMET00157 | |
| 0.101 | 0.053 | 0.124 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.103 0.051 DBMET00156 0.095 0.059 DBMET00157 0.122 0.038 DBMET00158 0.124 0.037 DBMET01351 | DBMET01351 | |
| 0.054 | 0.008 | 0.054 | Peroxisome proliferator-activated receptor alpha antagonist | 0.034 0.01 DBMET00156 | ||
| 0.053 | 0.008 | 0.053 | Prostaglandin EP4 antagonist | 0.049 0.009 DBMET00156 | ||
| 0.053 | 0.009 | 0.053 | Peroxisome proliferator-activated receptor delta antagonist | 0.053 0.009 DBMET00156 0.052 0.009 DBMET00158 0.051 0.009 DBMET01351 | ||
| 0.198 | 0.154 | 0.255 | 12-Lipoxygenase inhibitor | 0.234 0.119 DBMET00156 0.212 0.138 DBMET00158 0.255 0.106 DBMET01351 | DBMET01351 | |
| 0.154 | 0.11 | 0.185 | P-glycoprotein inhibitor | 0.185 0.075 DBMET00157 0.163 0.099 DBMET00158 | DBMET00157 | |
| 0.074 | 0.03 | 0.081 | MDM2 inhibitor | 0.076 0.025 DBMET00156 0.078 0.022 DBMET00158 0.081 0.019 DBMET01351 | DBMET01351 | |
| 0.057 | 0.014 | 0.065 | Liver X receptor alpha agonist | 0.065 0.01 DBMET00156 0.041 0.029 DBMET00158 0.048 0.021 DBMET01351 | DBMET00156 | |
| 0.054 | 0.012 | 0.055 | p53 inhibitor | 0.055 0.011 DBMET00156 0.033 0.028 DBMET00158 0.033 0.029 DBMET01351 | DBMET00156 | |
| 0.078 | 0.036 | 0.108 | Potassium channel large-conductance Ca-activated activator | 0.101 0.023 DBMET00156 0.079 0.036 DBMET00158 0.108 0.02 DBMET01351 | DBMET01351 | |
| 0.048 | 0.008 | 0.05 | Prostaglandin D2 agonist | 0.05 0.008 DBMET00156 0.031 0.02 DBMET00157 0.03 0.022 DBMET00158 0.032 0.02 DBMET01351 | DBMET00156 | |
| 0.135 | 0.096 | 0.148 | Heat shock protein 70 antagonist | 0.143 0.065 DBMET00156 0.14 0.076 DBMET00158 0.148 0.05 DBMET01351 | DBMET01351 | |
| 0.135 | 0.096 | 0.27 | GABA C receptor rho-2 antagonist | 0.154 0.069 DBMET00156 0.241 0.014 DBMET00158 0.27 0.008 DBMET01351 | DBMET01351 | |
| 0.043 | 0.005 | 0.154 | Thyroid hormone agonist | 0.074 0.003 DBMET00156 0.08 0.003 DBMET00158 0.154 0.002 DBMET01351 | DBMET01351 | |
| 0.047 | 0.01 | 0.047 | Carnitine palmitoyltransferase inhibitor | 0.038 0.018 DBMET00158 | ||
| 0.046 | 0.01 | 0.046 | Carnitine palmitoyltransferase 1 inhibitor | 0.038 0.017 DBMET00158 | ||
| 0.051 | 0.018 | 0.073 | Urate transporter 1 inhibitor | 0.073 0.009 DBMET00156 0.041 0.025 DBMET01351 | DBMET00156 | |
| 0.046 | 0.014 | 0.053 | Leukotriene C4 antagonist | 0.052 0.009 DBMET00156 0.047 0.013 DBMET00158 0.053 0.009 DBMET01351 | DBMET01351 | |
| 0.06 | 0.028 | 0.075 | Thromboxane A2 antagonist | 0.075 0.018 DBMET00156 0.043 0.042 DBMET00158 0.062 0.026 DBMET01351 | DBMET00156 | |
| 0.043 | 0.013 | 0.043 | Prostaglandin EP3 antagonist | 0.043 0.012 DBMET00156 | ||
| 0.174 | 0.143 | 0.268 | Nitric-oxide synthase stimulant | 0.188 0.11 DBMET00156 0.25 0.032 DBMET00158 0.268 0.022 DBMET01351 | DBMET01351 | |
| 0.066 | 0.037 | 0.078 | Prostaglandin F2 alpha antagonist | 0.078 0.024 DBMET00156 0.061 0.045 DBMET01351 | DBMET00156 | |
| 0.087 | 0.059 | 0.104 | Interleukin 5 antagonist | 0.099 0.043 DBMET00156 0.09 0.055 DBMET00158 0.104 0.037 DBMET01351 | DBMET01351 | |
| 0.057 | 0.03 | 0.058 | Sphingosine 1-phosphate receptor 5 agonist | 0.058 0.029 DBMET00156 0.057 0.03 DBMET00158 0.058 0.029 DBMET01351 | DBMET01351 | |
| 0.056 | 0.029 | 0.084 | Glucose-6-phosphate translocase inhibitor | 0.054 0.032 DBMET00156 0.084 0.01 DBMET00157 | DBMET00157 | |
| 0.033 | 0.009 | 0.036 | Prostaglandin EP1 antagonist | 0.036 0.009 DBMET00156 | DBMET00156 | |
| 0.062 | 0.038 | 0.097 | Androgen agonist | 0.097 0.016 DBMET00156 0.062 0.038 DBMET00158 0.096 0.016 DBMET01351 | DBMET00156 | |
| 0.037 | 0.014 | 0.053 | Liver X receptor beta antagonist | 0.053 0.007 DBMET00156 0.035 0.015 DBMET01351 | DBMET00156 | |
| 0.043 | 0.02 | 0.043 | Farnesoid X receptor agonist | 0.036 0.028 DBMET00156 | ||
| 0.026 | 0.005 | 0.077 | Thyroid hormone alpha antagonist | 0.041 0.004 DBMET00156 0.037 0.005 DBMET00158 0.077 0.004 DBMET01351 | DBMET01351 | |
| 0.024 | 0.005 | 0.034 | Thyroid hormone alpha agonist | 0.03 0.004 DBMET00156 0.027 0.004 DBMET00158 0.034 0.004 DBMET01351 | DBMET01351 | |
| 0.033 | 0.014 | 0.038 | Liver X receptor alpha antagonist | 0.038 0.01 DBMET00156 0.031 0.017 DBMET00158 0.036 0.012 DBMET01351 | DBMET00156 | |
| 0.037 | 0.019 | 0.057 | Peroxisome proliferator-activated receptor delta agonist | 0.057 0.011 DBMET00158 0.034 0.023 DBMET01351 | DBMET00158 | |
| 0.035 | 0.02 | 0.042 | Liver X receptor beta agonist | 0.042 0.014 DBMET00156 | DBMET00156 | |
| 0.054 | 0.039 | 0.074 | Thromboxane synthase inhibitor | 0.061 0.026 DBMET00156 0.063 0.023 DBMET00158 0.074 0.015 DBMET01351 | DBMET01351 | |
| 0.042 | 0.028 | 0.05 | Kainate receptor agonist | 0.043 0.024 DBMET00156 0.048 0.017 DBMET00158 0.05 0.014 DBMET01351 | DBMET01351 | |
| 0.044 | 0.03 | 0.291 | NMDA receptor subunit 3B antagonist | 0.143 0.007 DBMET00156 0.123 0.008 DBMET00158 0.291 0.004 DBMET01351 | DBMET01351 | |
| 0.126 | 0.112 | 0.138 | Pregnane X receptor agonist | 0.138 0.077 DBMET00156 | DBMET00156 | |
| 0.085 | 0.073 | 0.109 | Uric acid excretion stimulant | 0.109 0.045 DBMET00156 0.097 0.056 DBMET00157 0.105 0.048 DBMET01351 | DBMET00156 | |
| 0.066 | 0.054 | 0.088 | Prostaglandin-E synthase inhibitor | 0.088 0.034 DBMET00156 0.063 0.059 DBMET00158 0.083 0.037 DBMET01351 | DBMET00156 | |
| 0.079 | 0.068 | 0.079 | Factor XII inhibitor | |||
| 0.075 | 0.064 | 0.075 | MAP kinase 7 inhibitor | |||
| 0.033 | 0.024 | 0.053 | Free fatty acid receptor 1 antagonist | 0.053 0.008 DBMET00158 0.039 0.017 DBMET01351 | DBMET00158 | |
| 0.028 | 0.02 | 0.028 | Carnitine palmitoyltransferase 1A inhibitor | |||
| 0.03 | 0.023 | 0.035 | Liver X receptor antagonist | 0.035 0.017 DBMET00156 0.033 0.019 DBMET01351 | DBMET00156 | |
| 0.052 | 0.046 | 0.104 | Potassium channel Kv1.5 blocker | 0.104 0.017 DBMET00158 0.064 0.033 DBMET01351 | DBMET00158 | |
| 0.01 | 0.005 | 0.102 | Thyroid hormone beta agonist | 0.03 0.003 DBMET00156 0.036 0.003 DBMET00158 0.102 0.002 DBMET01351 | DBMET01351 | |
| 0.067 | 0.062 | 0.074 | Glycine receptor agonist | 0.074 0.048 DBMET00156 0.068 0.06 DBMET01351 | DBMET00156 | |
| 0.175 | 0.172 | 0.209 | Neuropeptide Y2 antagonist | 0.209 0.105 DBMET00156 | DBMET00156 | |
| 0.05 | 0.047 | 0.065 | Beta tubulin antagonist | 0.065 0.037 DBMET00158 | DBMET00158 | |
| 0.097 | 0.095 | 0.18 | Cell adhesion inhibitor | 0.18 0.031 DBMET00157 | DBMET00157 | |
| 0.134 | 0.132 | 0.242 | Lipocortins synthesis antagonist | 0.14 0.121 DBMET00156 0.228 0.041 DBMET00158 0.242 0.036 DBMET01351 | DBMET01351 | |
| 0.13 | 0.129 | 0.275 | DNA methyltransferase I inhibitor | 0.275 0.036 DBMET00158 0.264 0.041 DBMET01351 | DBMET00158 | |
| 0.033 | 0.033 | 0.033 | Glutamate (mGluR3) antagonist | 0.033 0.031 DBMET00156 | DBMET00156 | |
| 0.028 | 0.029 | 0.049 | ATP citrate lysase inhibitor | 0.049 0.008 DBMET00156 0.038 0.015 DBMET01351 | DBMET00156 | |
| 0.088 | 0.089 | 0.174 | AMP-activated protein kinase stimulant | 0.112 0.057 DBMET00156 0.174 0.016 DBMET00157 0.115 0.053 DBMET00158 0.144 0.032 DBMET01351 | DBMET00157 | |
| 0.116 | 0.118 | 0.168 | Insulin secretagoues | 0.118 0.114 DBMET00156 0.159 0.065 DBMET00157 0.162 0.063 DBMET00158 0.168 0.057 DBMET01351 | DBMET01351 | |
| 0.053 | 0.056 | 0.215 | NMDA 2C receptor antagonist | 0.097 0.017 DBMET00156 0.099 0.016 DBMET00158 0.215 0.005 DBMET01351 | DBMET01351 | |
| 0.077 | 0.079 | 0.101 | D-Ala-D-Ala ligase inhibitor | 0.09 0.045 DBMET00156 0.086 0.052 DBMET00158 0.101 0.028 DBMET01351 | DBMET01351 | |
| 0.033 | 0.037 | 0.089 | Kainate receptor antagonist | 0.062 0.015 DBMET00156 0.05 0.021 DBMET00158 0.089 0.009 DBMET01351 | DBMET01351 | |
| 0.177 | 0.182 | 0.478 | Tyrosine 3 hydroxylase inhibitor | 0.247 0.071 DBMET00156 0.35 0.016 DBMET00158 0.478 0.004 DBMET01351 | DBMET01351 | |
| 0.084 | 0.09 | 0.195 | Expectorant | 0.195 0.021 DBMET00157 0.128 0.046 DBMET00158 0.116 0.053 DBMET01351 | DBMET00157 | |
| 0.028 | 0.038 | 0.275 | NMDA receptor subunit 3A antagonist | 0.102 0.008 DBMET00156 0.1 0.008 DBMET00158 0.275 0.004 DBMET01351 | DBMET01351 | |
| 0.128 | 0.138 | 0.273 | Pyruvate kinase inhibitor | 0.149 0.116 DBMET00156 0.227 0.068 DBMET00158 0.273 0.055 DBMET01351 | DBMET01351 | |
| 0.052 | 0.064 | 0.077 | Enoyl-[acyl-carrier-protein] reductase inhibitor | 0.077 0.021 DBMET00156 | DBMET00156 | |
| 0.047 | 0.06 | 0.056 | Glucagon-like peptide 1 agonist | 0.056 0.051 DBMET00156 | DBMET00156 | |
| 0.197 | 0.211 | 0.512 | GABA C receptor rho-3 antagonist | 0.383 0.069 DBMET00156 0.326 0.099 DBMET00158 0.512 0.023 DBMET01351 | DBMET01351 | |
| 0.12 | 0.134 | 0.195 | Interferon gamma antagonist | 0.135 0.101 DBMET00156 0.175 0.053 DBMET00157 0.171 0.057 DBMET00158 0.195 0.043 DBMET01351 | DBMET01351 | |
| 0.122 | 0.138 | 0.193 | CF transmembrane conductance regulator agonist | 0.136 0.104 DBMET00156 0.128 0.122 DBMET00157 0.178 0.038 DBMET00158 0.193 0.026 DBMET01351 | DBMET01351 | |
| 0.053 | 0.068 | 0.061 | Phosphodiesterase 4B inhibitor | 0.061 0.056 DBMET00158 | DBMET00158 | |
| 0.049 | 0.066 | 0.06 | Pregnane X receptor antagonist | 0.06 0.032 DBMET00158 0.058 0.036 DBMET01351 | DBMET00158 | |
| 0.116 | 0.134 | 0.135 | Dual specificity phosphatase 3 inhibitor | 0.131 0.115 DBMET00156 0.135 0.11 DBMET01351 | DBMET01351 | |
| 0.015 | 0.036 | 0.021 | Lysophosphatidic acid 1 receptor antagonist | 0.021 0.015 DBMET00158 | DBMET00158 | |
| 0.108 | 0.13 | 0.129 | Sphingosine 1-phosphate receptor 2 antagonist | 0.118 0.103 DBMET00156 0.12 0.097 DBMET00158 0.129 0.076 DBMET01351 | DBMET01351 | |
| 0.084 | 0.106 | 0.109 | Interleukin 1b antagonist | 0.109 0.071 DBMET00158 | DBMET00158 | |
| 0.077 | 0.099 | 0.162 | Gastric antisecretory | 0.162 0.022 DBMET00158 0.136 0.033 DBMET01351 | DBMET00158 | |
| 0.077 | 0.1 | 0.146 | Xanthine oxidase inhibitor | 0.098 0.061 DBMET00156 0.093 0.067 DBMET00157 0.098 0.062 DBMET00158 0.146 0.036 DBMET01351 | DBMET01351 | |
| 0.12 | 0.145 | 0.323 | Platelet adhesion inhibitor | 0.323 0.027 DBMET00157 0.17 0.088 DBMET00158 0.179 0.083 DBMET01351 | DBMET00157 | |
| 0.061 | 0.086 | 0.094 | Macrophage migration inhibitory factor inhibitor | 0.073 0.061 DBMET00156 0.076 0.057 DBMET00158 0.094 0.038 DBMET01351 | DBMET01351 | |
| 0.099 | 0.125 | 0.121 | Antibacterial (Helicobacter pylori) | 0.121 0.08 DBMET00158 0.12 0.081 DBMET01351 | DBMET00158 | |
| 0.157 | 0.183 | 0.308 | 5 Hydroxytryptamine 1E antagonist | 0.307 0.026 DBMET00158 0.308 0.025 DBMET01351 | DBMET01351 | |
| 0.065 | 0.093 | 0.077 | Sphingosine 1-phosphate receptor antagonist | 0.077 0.052 DBMET00156 | DBMET00156 | |
| 0.013 | 0.043 | 0.122 | NMDA receptor glycine site antagonist | 0.024 0.018 DBMET00156 0.055 0.005 DBMET00158 0.122 0.004 DBMET01351 | DBMET01351 | |
| 0.022 | 0.052 | 0.059 | Melatonin 1 agonist | 0.059 0.007 DBMET00158 0.033 0.022 DBMET01351 | DBMET00158 | |
| 0.087 | 0.119 | 0.182 | Photosensitizer | 0.172 0.021 DBMET00158 0.182 0.017 DBMET01351 | DBMET01351 | |
| 0.034 | 0.066 | 0.047 | Plasminogen activator inhibitor antagonist | 0.045 0.04 DBMET00158 0.047 0.037 DBMET01351 | DBMET01351 | |
| 0.041 | 0.075 | 0.074 | Heparanase inhibitor | 0.074 0.009 DBMET00157 0.059 0.024 DBMET00158 0.054 0.036 DBMET01351 | DBMET00157 | |
| 0.061 | 0.095 | 0.104 | Cell adhesion molecule inhibitor | 0.104 0.032 DBMET00157 | DBMET00157 | |
| 0.02 | 0.055 | 0.061 | Melatonin 2 agonist | 0.061 0.008 DBMET00158 0.038 0.017 DBMET01351 | DBMET00158 | |
| 0.063 | 0.099 | 0.075 | Inducible nitric-oxide synthase inhibitor | 0.075 0.071 DBMET00158 0.074 0.072 DBMET01351 | DBMET00158 | |
| 0.117 | 0.154 | 0.142 | Interleukin 6 antagonist | 0.13 0.124 DBMET00158 0.142 0.103 DBMET01351 | DBMET01351 | |
| 0.039 | 0.076 | 0.119 | NMDA receptor glycine site agonist | 0.108 0.013 DBMET00158 0.119 0.009 DBMET01351 | DBMET01351 | |
| 0.019 | 0.056 | 0.037 | 5-Alpha-reductase inhibitor | 0.037 0.027 DBMET01351 | DBMET01351 | |
| 0.112 | 0.15 | 0.152 | Sphingosine 1-phosphate receptor 5 antagonist | 0.123 0.118 DBMET00156 0.141 0.077 DBMET00158 0.152 0.058 DBMET01351 | DBMET01351 | |
| 0.075 | 0.113 | 0.234 | GABA C receptor rho-1 antagonist | 0.096 0.067 DBMET00156 0.188 0.01 DBMET00158 0.234 0.005 DBMET01351 | DBMET01351 | |
| 0.045 | 0.084 | 0.166 | NMDA receptor agonist | 0.061 0.046 DBMET00156 0.119 0.013 DBMET00158 0.166 0.006 DBMET01351 | DBMET01351 | |
| 0.123 | 0.162 | 0.236 | ATPase inhibitor | 0.154 0.095 DBMET00157 0.225 0.022 DBMET00158 0.236 0.018 DBMET01351 | DBMET01351 | |
| 0.174 | 0.216 | 0.233 | Caspase 3 stimulant | 0.233 0.128 DBMET00157 0.205 0.162 DBMET00158 | DBMET00157 | |
| 0.104 | 0.147 | 0.196 | Hexokinase inhibitor | 0.131 0.103 DBMET00156 0.196 0.038 DBMET00157 | DBMET00157 | |
| 0.051 | 0.094 | 0.073 | Glutamate (mGluR7) antagonist | 0.073 0.037 DBMET00158 | DBMET00158 | |
| 0.007 | 0.05 | 0.018 | Endothelin B receptor antagonist | 0.018 0.013 DBMET00158 | DBMET00158 | |
| 0.064 | 0.109 | 0.132 | HIV-1 integrase (Overall Integration) inhibitor | 0.083 0.074 DBMET00156 0.103 0.052 DBMET00158 0.132 0.033 DBMET01351 | DBMET01351 | |
| 0.047 | 0.092 | 0.089 | Phosphodiesterase 4D inhibitor | 0.089 0.042 DBMET00158 | DBMET00158 | |
| 0.019 | 0.065 | 0.045 | Melatonin agonist | 0.045 0.011 DBMET00158 | DBMET00158 | |
| 0.115 | 0.162 | 0.257 | DNA methylase inhibitor | 0.158 0.111 DBMET00157 0.257 0.044 DBMET00158 0.246 0.051 DBMET01351 | DBMET00158 | |
| 0.013 | 0.06 | 0.029 | Endothelin receptor antagonist | 0.029 0.018 DBMET00158 | DBMET00158 | |
| 0.108 | 0.156 | 0.138 | Neuropeptide Y1 antagonist | 0.133 0.094 DBMET00158 0.138 0.085 DBMET01351 | DBMET01351 | |
| 0.044 | 0.092 | 0.162 | Catalase inhibitor | 0.138 0.029 DBMET00158 0.162 0.023 DBMET01351 | DBMET01351 | |
| 0.047 | 0.098 | 0.064 | Ryanodine receptor antagonist | 0.064 0.027 DBMET00158 | DBMET00158 | |
| 0.005 | 0.056 | 0.021 | Kainate receptor 1 antagonist | 0.021 0.015 DBMET01351 | DBMET01351 | |
| 0.059 | 0.11 | 0.089 | Antineoplastic alkaloid | 0.075 0.072 DBMET00158 0.089 0.055 DBMET01351 | DBMET01351 | |
| 0.04 | 0.093 | 0.074 | Nitric oxide donor | 0.074 0.029 DBMET00157 | DBMET00157 | |
| 0.028 | 0.082 | 0.044 | Dihydrofolate reductase inhibitor | 0.044 0.029 DBMET00158 | DBMET00158 | |
| 0.011 | 0.068 | 0.026 | Melatonin antagonist | 0.026 0.024 DBMET00158 | DBMET00158 | |
| 0.022 | 0.078 | 0.039 | Estrogen-related receptor beta antagonist | 0.033 0.021 DBMET00156 0.039 0.012 DBMET01351 | DBMET01351 | |
| 0.05 | 0.107 | 0.075 | HIV-1 integrase inhibitor | 0.068 0.052 DBMET00156 0.075 0.042 DBMET01351 | DBMET01351 | |
| 0.164 | 0.221 | 0.481 | Vasodilator, peripheral | 0.481 0.032 DBMET00158 0.456 0.039 DBMET01351 | DBMET00158 | |
| 0.064 | 0.122 | 0.121 | NADH dehydrogenase inhibitor | 0.079 0.076 DBMET00156 0.121 0.028 DBMET00157 0.091 0.055 DBMET00158 0.113 0.033 DBMET01351 | DBMET00157 | |
| 0.005 | 0.063 | 0.013 | Egl nine homolog 1 inhibitor | 0.013 0.012 DBMET01351 | DBMET01351 | |
| 0.023 | 0.081 | 0.055 | Phosphorylase inhibitor | 0.055 0.027 DBMET01351 | DBMET01351 | |
| 0.106 | 0.165 | 0.293 | Nitric oxide antagonist | 0.293 0.042 DBMET00157 0.13 0.118 DBMET00158 0.145 0.099 DBMET01351 | DBMET00157 | |
| 0.089 | 0.149 | 0.137 | Protein kinase stimulant | 0.122 0.09 DBMET00158 0.137 0.077 DBMET01351 | DBMET01351 | |
| 0.107 | 0.167 | 0.144 | Dual specificity phosphatase inhibitor | 0.144 0.101 DBMET01351 | DBMET01351 | |
| 0.067 | 0.127 | 0.093 | Lanosterol 14 alpha demethylase inhibitor | 0.093 0.067 DBMET00156 0.093 0.066 DBMET01351 | DBMET01351 | |
| 0.088 | 0.149 | 0.21 | Thrombolytic | 0.21 0.047 DBMET00157 0.169 0.069 DBMET00158 0.201 0.052 DBMET01351 | DBMET00157 | |
| 0.006 | 0.068 | 0.012 | Melatonin 2 antagonist | 0.012 0.008 DBMET00158 | DBMET00158 | |
| 0.04 | 0.103 | 0.076 | Purinergic P2X1 antagonist | 0.055 0.052 DBMET00156 0.076 0.027 DBMET01351 | DBMET01351 | |
| 0.071 | 0.134 | 0.087 | Glutamate release inhibitor | 0.087 0.07 DBMET00158 | DBMET00158 | |
| 0.12 | 0.186 | 0.15 | Ca2+-transporting ATPase inhibitor | 0.131 0.114 DBMET00156 0.138 0.081 DBMET00158 0.15 0.043 DBMET01351 | DBMET01351 | |
| 0.128 | 0.195 | 0.453 | Antioxidant | 0.184 0.128 DBMET00156 0.453 0.026 DBMET00157 0.209 0.108 DBMET00158 0.29 0.065 DBMET01351 | DBMET00157 | |
| 0.021 | 0.088 | 0.099 | NMDA 2A receptor antagonist | 0.071 0.024 DBMET00156 0.099 0.013 DBMET01351 | DBMET01351 | |
| 0.029 | 0.096 | 0.054 | GABA B receptor antagonist | 0.045 0.026 DBMET00158 0.054 0.016 DBMET01351 | DBMET01351 | |
| 0.024 | 0.092 | 0.064 | Fructose-1,6-bisphosphatase inhibitor | 0.064 0.015 DBMET00158 0.06 0.017 DBMET01351 | DBMET00158 | |
| 0.021 | 0.089 | 0.09 | Melatonin receptor 1A agonist | 0.09 0.004 DBMET00158 0.035 0.019 DBMET01351 | DBMET00158 | |
| 0.084 | 0.153 | 0.192 | Interleukin 4 antagonist | 0.119 0.087 DBMET00156 0.12 0.086 DBMET00157 0.147 0.052 DBMET00158 0.192 0.025 DBMET01351 | DBMET01351 | |
| 0.034 | 0.105 | 0.052 | 3-Oxoacyl-[acyl-carrier-protein] synthase inhibitor | 0.052 0.051 DBMET00156 | DBMET00156 | |
| 0.104 | 0.176 | 0.183 | Melanin inhibitor | 0.134 0.107 DBMET00157 0.171 0.058 DBMET00158 0.183 0.05 DBMET01351 | DBMET01351 | |
| 0.08 | 0.153 | 0.141 | Estrogen antagonist | 0.128 0.041 DBMET00156 0.141 0.027 DBMET01351 | DBMET01351 | |
| 0.071 | 0.145 | 0.165 | Toll-Like receptor 4 antagonist | 0.165 0.014 DBMET00157 | DBMET00157 | |
| 0.103 | 0.178 | 0.273 | Aryl hydrocarbon receptor agonist | 0.273 0.07 DBMET00158 0.24 0.083 DBMET01351 | DBMET00158 | |
| 0.05 | 0.126 | 0.348 | NMDA receptor antagonist | 0.124 0.034 DBMET00156 0.144 0.026 DBMET00158 0.348 0.005 DBMET01351 | DBMET01351 | |
| 0.025 | 0.102 | 0.055 | Alpha tubulin antagonist | 0.055 0.035 DBMET00158 | DBMET00158 | |
| 0.011 | 0.089 | 0.034 | Progesterone antagonist | 0.03 0.028 DBMET00158 0.034 0.026 DBMET01351 | DBMET01351 | |
| 0.065 | 0.143 | 0.1 | Estrogen-related receptor beta agonist | 0.086 0.049 DBMET00158 0.1 0.024 DBMET01351 | DBMET01351 | |
| 0.041 | 0.12 | 0.117 | NAD(P)H dehydrogenase (quinone) inhibitor | 0.09 0.044 DBMET00158 0.117 0.03 DBMET01351 | DBMET01351 | |
| 0.015 | 0.093 | 0.023 | Vitamin D receptor antagonist | 0.022 0.016 DBMET00158 0.023 0.014 DBMET01351 | DBMET01351 | |
| 0.064 | 0.145 | 0.078 | Vanilloid agonist | 0.078 0.077 DBMET01351 | DBMET01351 | |
| 0.024 | 0.107 | 0.05 | Mineralocorticoid receptor antagonist | 0.05 0.03 DBMET00158 0.05 0.03 DBMET01351 | DBMET01351 | |
| 0.126 | 0.21 | 0.204 | Cardiotonic | 0.204 0.115 DBMET00158 0.18 0.139 DBMET01351 | DBMET00158 | |
| 0.04 | 0.124 | 0.073 | Adenine nucleotide translocase inhibitor | 0.073 0.013 DBMET00157 | DBMET00157 | |
| 0.028 | 0.113 | 0.275 | Selectin antagonist | 0.275 0.007 DBMET00157 | DBMET00157 | |
| 0.014 | 0.099 | 0.034 | Retinoid X alpha receptor agonist | 0.034 0.025 DBMET01351 | DBMET01351 | |
| 0.026 | 0.111 | 0.045 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | 0.045 0.022 DBMET01351 | DBMET01351 | |
| 0.063 | 0.148 | 0.115 | M18 aspartyl aminopeptidase inhibitor | 0.105 0.086 DBMET00156 0.115 0.075 DBMET01351 | DBMET01351 | |
| 0.043 | 0.129 | 0.058 | Lipocortins synthesis agonist | 0.058 0.04 DBMET00157 | DBMET00157 | |
| 0.025 | 0.112 | 0.059 | Lysophosphatidic acid 3 receptor antagonist | 0.059 0.024 DBMET00158 0.048 0.038 DBMET01351 | DBMET00158 | |
| 0.031 | 0.12 | 0.051 | Bombesin 2 receptor antagonist | 0.045 0.043 DBMET00158 0.051 0.032 DBMET01351 | DBMET01351 | |
| 0.059 | 0.148 | 0.257 | Ferrochelatase inhibitor | 0.094 0.078 DBMET00156 0.166 0.032 DBMET00158 0.257 0.012 DBMET01351 | DBMET01351 | |
| 0.07 | 0.159 | 0.307 | Adenylate kinase inhibitor | 0.232 0.011 DBMET00158 0.307 0.006 DBMET01351 | DBMET01351 | |
| 0.048 | 0.139 | 0.136 | Glycine receptor antagonist | 0.114 0.022 DBMET00158 0.136 0.011 DBMET01351 | DBMET01351 | |
| 0.044 | 0.137 | 0.076 | CDC25A inhibitor | 0.076 0.048 DBMET01351 | DBMET01351 | |
| 0.062 | 0.156 | 0.093 | Interleukin 1 beta converting enzyme inhibitor | 0.085 0.08 DBMET00158 0.093 0.067 DBMET01351 | DBMET01351 | |
| 0.072 | 0.168 | 0.123 | Aldehyde dehydrogenase inhibitor | 0.104 0.091 DBMET00156 0.123 0.067 DBMET01351 | DBMET01351 | |
| 0.147 | 0.244 | 0.318 | Vasodilator, coronary | 0.318 0.074 DBMET00157 0.292 0.094 DBMET00158 0.256 0.129 DBMET01351 | DBMET00157 | |
| 0.021 | 0.118 | 0.038 | Retinoid X receptor antagonist | 0.038 0.027 DBMET01351 | DBMET01351 | |
| 0.053 | 0.151 | 0.074 | Glutathione S-transferase inhibitor | 0.074 0.071 DBMET01351 | DBMET01351 | |
| 0.019 | 0.117 | 0.032 | Retinoid X alpha receptor antagonist | 0.032 0.028 DBMET01351 | DBMET01351 | |
| 0.044 | 0.144 | 0.17 | Monophenol monooxygenase inhibitor | 0.17 0.04 DBMET00157 0.117 0.063 DBMET01351 | DBMET00157 | |
| 0.159 | 0.26 | 0.408 | 15-Lipoxygenase inhibitor | 0.211 0.201 DBMET00156 0.347 0.101 DBMET00158 0.408 0.071 DBMET01351 | DBMET01351 | |
| 0.089 | 0.194 | 0.14 | Vanilloid 1 agonist | 0.14 0.05 DBMET00158 0.137 0.054 DBMET01351 | DBMET00158 | |
| 0.15 | 0.255 | 0.435 | Immunosuppressant | 0.435 0.052 DBMET00157 | DBMET00157 | |
| 0.059 | 0.165 | 0.117 | Granulocyte macrophage colony stimulating factor agonist | 0.117 0.018 DBMET00158 0.095 0.043 DBMET01351 | DBMET00158 | |
| 0.109 | 0.216 | 0.227 | Neurotrophic factor enhancer | 0.171 0.109 DBMET00156 0.162 0.121 DBMET00158 0.227 0.053 DBMET01351 | DBMET01351 | |
| 0.049 | 0.156 | 0.169 | Mediator release inhibitor | 0.138 0.035 DBMET00158 0.169 0.022 DBMET01351 | DBMET01351 | |
| 0.07 | 0.181 | 0.185 | Toll-Like receptor 2 antagonist | 0.161 0.045 DBMET00158 0.185 0.031 DBMET01351 | DBMET01351 | |
| 0.094 | 0.205 | 0.299 | Hepatoprotectant | 0.299 0.03 DBMET00157 0.157 0.103 DBMET00158 0.173 0.086 DBMET01351 | DBMET00157 | |
| 0.017 | 0.129 | 0.028 | Toll-Like receptor 4 agonist | 0.028 0.015 DBMET00157 | DBMET00157 | |
| 0.152 | 0.268 | 0.349 | Apoptosis antagonist | 0.349 0.056 DBMET00157 0.204 0.173 DBMET00158 0.24 0.137 DBMET01351 | DBMET00157 | |
| 0.051 | 0.167 | 0.088 | Breast cancer-resistant protein inhibitor | 0.088 0.068 DBMET00158 | DBMET00158 | |
| 0.035 | 0.152 | 0.16 | Platelet growth factor antagonist | 0.16 0.016 DBMET00158 0.125 0.027 DBMET01351 | DBMET00158 | |
| 0.05 | 0.17 | 0.076 | Estrogen receptor alpha antagonist | 0.076 0.056 DBMET01351 | DBMET01351 | |
| 0.121 | 0.242 | 0.295 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.272 0.033 DBMET00158 0.295 0.025 DBMET01351 | DBMET01351 | |
| 0.048 | 0.168 | 0.139 | Platelet activating factor antagonist | 0.139 0.051 DBMET00158 | DBMET00158 | |
| 0.101 | 0.225 | 0.389 | Free radical scavenger | 0.149 0.146 DBMET00156 0.389 0.031 DBMET00157 0.201 0.097 DBMET00158 0.285 0.056 DBMET01351 | DBMET00157 | |
| 0.093 | 0.217 | 0.163 | Anticonvulsant | 0.158 0.12 DBMET00158 0.163 0.114 DBMET01351 | DBMET01351 | |
| 0.008 | 0.133 | 0.028 | AMPA 2 receptor antagonist | 0.028 0.022 DBMET01351 | DBMET01351 | |
| 0.119 | 0.248 | 0.279 | Superoxide dismutase inhibitor | 0.271 0.062 DBMET00158 0.279 0.059 DBMET01351 | DBMET01351 | |
| 0.021 | 0.15 | 0.038 | Glutamate (mGluR8) agonist | 0.038 0.026 DBMET01351 | DBMET01351 | |
| 0.057 | 0.186 | 0.19 | Beta glucuronidase inhibitor | 0.19 0.014 DBMET00157 0.128 0.039 DBMET00158 0.157 0.022 DBMET01351 | DBMET00157 | |
| 0.037 | 0.169 | 0.065 | Calcium channel L-type blocker | 0.065 0.06 DBMET00158 | DBMET00158 | |
| 0.054 | 0.186 | 0.123 | Estrogen receptor beta antagonist | 0.11 0.046 DBMET00156 0.123 0.029 DBMET01351 | DBMET01351 | |
| 0.038 | 0.171 | 0.073 | Beta 3 adrenoreceptor antagonist | 0.065 0.043 DBMET00158 0.073 0.03 DBMET01351 | DBMET01351 | |
| 0.056 | 0.189 | 0.24 | GABA C receptor antagonist | 0.096 0.084 DBMET00156 0.158 0.026 DBMET00158 0.24 0.007 DBMET01351 | DBMET01351 | |
| 0.042 | 0.176 | 0.16 | Alcohol dehydrogenase inhibitor | 0.093 0.061 DBMET00156 0.087 0.069 DBMET00158 0.16 0.018 DBMET01351 | DBMET01351 | |
| 0.012 | 0.148 | 0.029 | Lysophosphatidic acid 2 receptor antagonist | 0.029 0.023 DBMET00158 | DBMET00158 | |
| 0.027 | 0.167 | 0.048 | Beta adrenoreceptor agonist | 0.048 0.022 DBMET01351 | DBMET01351 | |
| 0.008 | 0.148 | 0.036 | Kainate receptor 2 antagonist | 0.036 0.025 DBMET01351 | DBMET01351 | |
| 0.039 | 0.179 | 0.171 | Topoisomerase I inhibitor | 0.171 0.034 DBMET00157 0.098 0.072 DBMET01351 | DBMET00157 | |
| 0.016 | 0.158 | 0.055 | Xanthine dehydrogenase inhibitor | 0.055 0.042 DBMET01351 | DBMET01351 | |
| 0.051 | 0.194 | 0.169 | Glutamate receptor antagonist | 0.107 0.088 DBMET00158 0.169 0.039 DBMET01351 | DBMET01351 | |
| 0.042 | 0.185 | 0.064 | Glutamate (mGluR6) antagonist | 0.064 0.055 DBMET01351 | DBMET01351 | |
| 0.055 | 0.198 | 0.094 | Electrolyte absorption antagonist | 0.094 0.067 DBMET01351 | DBMET01351 | |
| 0.036 | 0.18 | 0.071 | GABA aminotransferase inhibitor | 0.071 0.059 DBMET01351 | DBMET01351 | |
| 0.069 | 0.216 | 0.132 | Protein-tyrosine phosphatase inhibitor | 0.132 0.099 DBMET01351 | DBMET01351 | |
| 0.06 | 0.208 | 0.145 | Interleukin 12 antagonist | 0.124 0.025 DBMET00158 0.145 0.014 DBMET01351 | DBMET01351 | |
| 0.031 | 0.18 | 0.077 | Topoisomerase II alpha inhibitor | 0.077 0.055 DBMET00157 | DBMET00157 | |
| 0.014 | 0.163 | 0.061 | Aromatase inhibitor | 0.061 0.041 DBMET01351 | DBMET01351 | |
| 0.045 | 0.195 | 0.098 | ATPase (Vacuolar H+) inhibitor | 0.083 0.072 DBMET00157 0.098 0.043 DBMET00158 0.087 0.061 DBMET01351 | DBMET00158 | |
| 0.056 | 0.207 | 0.107 | M17 leucyl aminopeptidase inhibitor | 0.107 0.092 DBMET00158 0.104 0.096 DBMET01351 | DBMET00158 | |
| 0.007 | 0.161 | 0.03 | Sodium/glucose cotransporter 2 inhibitor | 0.03 0.013 DBMET00157 | DBMET00157 | |
| 0.028 | 0.184 | 0.175 | Glutamate decarboxylase inhibitor | 0.064 0.063 DBMET00156 0.086 0.039 DBMET00158 0.175 0.009 DBMET01351 | DBMET01351 | |
| 0.055 | 0.212 | 0.13 | Nav1.4 sodium channel blocker | 0.097 0.081 DBMET00158 0.13 0.044 DBMET01351 | DBMET01351 | |
| 0.079 | 0.239 | 0.155 | Antimitotic | 0.155 0.116 DBMET00158 | DBMET00158 | |
| 0.03 | 0.192 | 0.118 | Androgen antagonist | 0.076 0.07 DBMET00158 0.118 0.034 DBMET01351 | DBMET01351 | |
| 0.045 | 0.208 | 0.346 | GABA C receptor agonist | 0.194 0.021 DBMET00158 0.346 0.007 DBMET01351 | DBMET01351 | |
| 0.046 | 0.211 | 0.136 | Triose-phosphate isomerase inhibitor | 0.094 0.054 DBMET00158 0.136 0.025 DBMET01351 | DBMET01351 | |
| 0.007 | 0.172 | 0.045 | AMPA 3 receptor antagonist | 0.045 0.011 DBMET01351 | DBMET01351 | |
| 0.046 | 0.211 | 0.215 | 5 Hydroxytryptamine 3A agonist | 0.159 0.031 DBMET00158 0.215 0.011 DBMET01351 | DBMET01351 | |
| 0.051 | 0.217 | 0.225 | Adenylate cyclase inhibitor | 0.151 0.044 DBMET00158 0.225 0.022 DBMET01351 | DBMET01351 | |
| 0.064 | 0.231 | 0.521 | Peroxidase inhibitor | 0.127 0.094 DBMET00156 0.31 0.035 DBMET00158 0.521 0.008 DBMET01351 | DBMET01351 | |
| 0.05 | 0.216 | 0.154 | Carbonic anhydrase III inhibitor | 0.106 0.056 DBMET00158 0.154 0.027 DBMET01351 | DBMET01351 | |
| 0.023 | 0.191 | 0.049 | Aldosterone antagonist | 0.049 0.031 DBMET00158 0.047 0.034 DBMET01351 | DBMET00158 | |
| 0.027 | 0.196 | 0.112 | Platelet activating factor beta antagonist | 0.112 0.055 DBMET00158 | DBMET00158 | |
| 0.034 | 0.204 | 0.092 | Protein-tyrosine phosphatase 1B inhibitor | 0.092 0.087 DBMET01351 | DBMET01351 | |
| 0.125 | 0.296 | 0.486 | Alpha-glucosidase inhibitor | 0.486 0.085 DBMET00157 0.254 0.185 DBMET01351 | DBMET00157 | |
| 0.016 | 0.188 | 0.07 | AMPA 4 receptor antagonist | 0.07 0.008 DBMET01351 | DBMET01351 | |
| 0.051 | 0.225 | 0.216 | Lipid peroxidase inhibitor | 0.216 0.035 DBMET00157 0.159 0.062 DBMET01351 | DBMET00157 | |
| 0.024 | 0.199 | 0.27 | Porphobilinogen synthase inhibitor | 0.064 0.062 DBMET00156 0.096 0.038 DBMET00158 0.27 0.006 DBMET01351 | DBMET01351 | |
| 0.08 | 0.255 | 0.169 | Glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase inhibitor | 0.169 0.122 DBMET00158 0.161 0.129 DBMET01351 | DBMET00158 | |
| 0.009 | 0.189 | 0.078 | AMPA receptor antagonist | 0.078 0.018 DBMET01351 | DBMET01351 | |
| 0.083 | 0.263 | 0.226 | Spasmolytic | 0.206 0.114 DBMET00158 0.226 0.102 DBMET01351 | DBMET01351 | |
| 0.023 | 0.205 | 0.218 | Phenylalanine 4-hydroxylase inhibitor | 0.069 0.048 DBMET00156 0.071 0.045 DBMET00158 0.218 0.006 DBMET01351 | DBMET01351 | |
| 0.079 | 0.263 | 0.182 | Adenylate cyclase stimulant | 0.15 0.062 DBMET00158 0.182 0.024 DBMET01351 | DBMET01351 | |
| 0.039 | 0.224 | 0.182 | Creatine kinase inhibitor | 0.119 0.041 DBMET00156 0.182 0.014 DBMET01351 | DBMET01351 | |
| 0.037 | 0.226 | 0.063 | Beta 2 adrenoreceptor agonist | 0.063 0.036 DBMET01351 | DBMET01351 | |
| 0.06 | 0.251 | 0.144 | Anticoagulant | 0.144 0.086 DBMET00157 | DBMET00157 | |
| 0.049 | 0.24 | 0.132 | Bone formation stimulant | 0.104 0.102 DBMET00158 0.132 0.075 DBMET01351 | DBMET01351 | |
| 0.012 | 0.205 | 0.114 | NMDA 2 receptor antagonist | 0.114 0.026 DBMET01351 | DBMET01351 | |
| 0.057 | 0.25 | 0.153 | Amyloid beta aggregation inhibitor | 0.153 0.105 DBMET01351 | DBMET01351 | |
| 0.042 | 0.236 | 0.118 | Anabolic | 0.118 0.041 DBMET01351 | DBMET01351 | |
| 0.027 | 0.225 | 0.124 | Calcium antagonist | 0.124 0.033 DBMET00158 | DBMET00158 | |
| 0.049 | 0.248 | 0.212 | Alpha-N-acetylglucosaminidase inhibitor | 0.128 0.07 DBMET00158 0.212 0.031 DBMET01351 | DBMET01351 | |
| 0.017 | 0.219 | 0.077 | Protein 50S ribosomal subunit inhibitor | 0.077 0.021 DBMET00157 | DBMET00157 | |
| 0.019 | 0.222 | 0.05 | Aconitate hydratase inhibitor | 0.05 0.038 DBMET01351 | DBMET01351 | |
| 0.021 | 0.225 | 0.046 | Glucose-6-phosphate isomerase inhibitor | 0.046 0.036 DBMET01351 | DBMET01351 | |
| 0.008 | 0.215 | 0.026 | Sodium/glucose cotransporter inhibitor | 0.026 0.016 DBMET00157 | DBMET00157 | |
| 0.061 | 0.273 | 0.171 | Cell wall synthesis inhibitor | 0.171 0.047 DBMET00157 0.159 0.057 DBMET01351 | DBMET00157 | |
| 0.023 | 0.236 | 0.069 | Topoisomerase II beta inhibitor | 0.069 0.017 DBMET01351 | DBMET01351 | |
| 0.02 | 0.235 | 0.075 | Carbonic anhydrase VA inhibitor | 0.075 0.041 DBMET01351 | DBMET01351 | |
| 0.11 | 0.325 | 0.305 | RNA-directed DNA polymerase inhibitor | 0.251 0.048 DBMET00158 0.305 0.031 DBMET01351 | DBMET01351 | |
| 0.09 | 0.306 | 0.232 | DNA damaging | 0.226 0.095 DBMET00158 0.232 0.091 DBMET01351 | DBMET01351 | |
| 0.049 | 0.266 | 0.111 | Microtubule formation inhibitor | 0.099 0.092 DBMET00157 0.111 0.072 DBMET00158 0.102 0.087 DBMET01351 | DBMET00158 | |
| 0.049 | 0.266 | 0.108 | Carbonic anhydrase XV inhibitor | 0.097 0.072 DBMET00158 0.108 0.057 DBMET01351 | DBMET01351 | |
| 0.069 | 0.286 | 0.171 | NOS3 expression enhancer | 0.171 0.055 DBMET00157 0.128 0.1 DBMET01351 | DBMET00157 | |
| 0.072 | 0.29 | 0.15 | Hemostatic | 0.15 0.068 DBMET00157 | DBMET00157 | |
| 0.024 | 0.245 | 0.076 | Aminopeptidase I inhibitor | 0.076 0.046 DBMET01351 | DBMET01351 | |
| 0.035 | 0.257 | 0.101 | Keratolytic | 0.08 0.049 DBMET00158 0.101 0.03 DBMET01351 | DBMET01351 | |
| 0.024 | 0.247 | 0.08 | Fibroblast growth factor 1 antagonist | 0.08 0.074 DBMET00158 | DBMET00158 | |
| 0.017 | 0.24 | 0.074 | Beta 1 adrenoreceptor antagonist | 0.071 0.025 DBMET00158 0.074 0.022 DBMET01351 | DBMET01351 | |
| 0.039 | 0.263 | 0.13 | Alkylator | 0.13 0.059 DBMET00157 0.105 0.083 DBMET00158 0.121 0.068 DBMET01351 | DBMET00157 | |
| 0.023 | 0.249 | 0.074 | Carbonic anhydrase XIII inhibitor | 0.074 0.054 DBMET01351 | DBMET01351 | |
| 0.003 | 0.229 | 0.04 | AMPA 1 receptor antagonist | 0.04 0.015 DBMET01351 | DBMET01351 | |
| 0.017 | 0.245 | 0.066 | Carbonic anhydrase V inhibitor | 0.066 0.047 DBMET01351 | DBMET01351 | |
| 0.07 | 0.299 | 0.177 | Growth hormone agonist | 0.134 0.102 DBMET00158 0.177 0.069 DBMET01351 | DBMET01351 | |
| 0.019 | 0.254 | 0.061 | Phosphodiesterase III inhibitor | 0.061 0.051 DBMET00158 | DBMET00158 | |
| 0.079 | 0.315 | 0.24 | Focal adhesion kinase 2 inhibitor | 0.24 0.043 DBMET00158 0.176 0.092 DBMET01351 | DBMET00158 | |
| 0.015 | 0.251 | 0.073 | Biliverdin reductase inhibitor | 0.073 0.03 DBMET01351 | DBMET01351 | |
| 0.039 | 0.276 | 0.161 | Proto-oncogene tyrosine-protein kinase Yes inhibitor | 0.161 0.056 DBMET01351 | DBMET01351 | |
| 0.03 | 0.269 | 0.084 | Glutamate dehydrogenase inhibitor | 0.084 0.041 DBMET01351 | DBMET01351 | |
| 0.028 | 0.268 | 0.103 | Interferon agonist | 0.096 0.032 DBMET00158 0.103 0.026 DBMET01351 | DBMET01351 | |
| 0.033 | 0.279 | 0.208 | Prolactin inhibitor | 0.14 0.026 DBMET00158 0.208 0.008 DBMET01351 | DBMET01351 | |
| 0.013 | 0.261 | 0.132 | Alcohol oxidase inhibitor | 0.132 0.012 DBMET01351 | DBMET01351 | |
| 0.018 | 0.266 | 0.063 | 3(or 17)beta-hydroxysteroid dehydrogenase inhibitor | 0.063 0.027 DBMET01351 | DBMET01351 | |
| 0.013 | 0.263 | 0.092 | Phosphofructokinase-1 inhibitor | 0.092 0.035 DBMET01351 | DBMET01351 | |
| 0.014 | 0.265 | 0.062 | Carbamoyl phosphate synthetase inhibitor | 0.062 0.041 DBMET01351 | DBMET01351 | |
| 0.048 | 0.3 | 0.418 | Angiogenesis stimulant | 0.418 0.019 DBMET00157 0.169 0.111 DBMET01351 | DBMET00157 | |
| 0.031 | 0.284 | 0.106 | Topoisomerase II inhibitor | 0.106 0.08 DBMET00157 | DBMET00157 | |
| 0.022 | 0.276 | 0.092 | Beta adrenoreceptor antagonist | 0.083 0.025 DBMET00158 0.092 0.02 DBMET01351 | DBMET01351 | |
| 0.025 | 0.281 | 0.094 | Adrenaline agonist | 0.094 0.042 DBMET01351 | DBMET01351 | |
| 0.109 | 0.368 | 0.295 | Peptidyltransferase inhibitor | 0.295 0.026 DBMET00157 0.171 0.145 DBMET00158 0.221 0.075 DBMET01351 | DBMET00157 | |
| 0.009 | 0.272 | 0.054 | Thymidylate synthase inhibitor | 0.054 0.023 DBMET01351 | DBMET01351 | |
| 0.026 | 0.291 | 0.099 | Histamine N-methyltransferase inhibitor | 0.099 0.047 DBMET01351 | DBMET01351 | |
| 0.04 | 0.308 | 0.1 | Beta amyloid protein antagonist | 0.1 0.09 DBMET00158 | DBMET00158 | |
| 0.01 | 0.28 | 0.097 | Antineoplastic antibiotic | 0.097 0.048 DBMET00157 | DBMET00157 | |
| 0.025 | 0.309 | 0.08 | Interferon inducer | 0.07 0.035 DBMET00158 0.08 0.024 DBMET01351 | DBMET01351 | |
| 0.092 | 0.378 | 0.129 | CC chemokine 6 receptor antagonist | 0.129 0.076 DBMET00157 | DBMET00157 | |
| 0.05 | 0.339 | 0.09 | CC chemokine 5 receptor agonist | 0.09 0.037 DBMET01351 | DBMET01351 | |
| 0.027 | 0.317 | 0.119 | Aminopeptidase B inhibitor | 0.119 0.053 DBMET01351 | DBMET01351 | |
| 0.015 | 0.307 | 0.063 | Beta 2 adrenoreceptor antagonist | 0.049 0.038 DBMET00158 0.063 0.022 DBMET01351 | DBMET01351 | |
| 0.007 | 0.305 | 0.04 | Nicotinic acid receptor agonist | 0.04 0.021 DBMET01351 | DBMET01351 | |
| 0.028 | 0.327 | 0.107 | Carbonic anhydrase VI inhibitor | 0.074 0.066 DBMET00158 0.107 0.035 DBMET01351 | DBMET01351 | |
| 0.007 | 0.308 | 0.057 | Dopamine D5 agonist | 0.057 0.013 DBMET01351 | DBMET01351 | |
| 0.031 | 0.333 | 0.106 | Chelator | 0.106 0.069 DBMET01351 | DBMET01351 | |
| 0.025 | 0.327 | 0.081 | Myeloperoxidase inhibitor | 0.081 0.065 DBMET01351 | DBMET01351 | |
| 0.011 | 0.314 | 0.099 | Argininosuccinate synthase inhibitor | 0.057 0.039 DBMET00158 0.099 0.019 DBMET01351 | DBMET01351 | |
| 0.049 | 0.353 | 0.354 | Immunostimulant | 0.354 0.063 DBMET00157 0.222 0.108 DBMET01351 | DBMET00157 | |
| 0.059 | 0.368 | 0.238 | Vasodilator | 0.238 0.076 DBMET00157 0.215 0.093 DBMET00158 0.229 0.083 DBMET01351 | DBMET00157 | |
| 0.028 | 0.35 | 0.102 | UDP-glucose 4-epimerase inhibitor | 0.086 0.079 DBMET00157 0.102 0.059 DBMET01351 | DBMET01351 | |
| 0.075 | 0.397 | 0.155 | Proto-oncogene tyrosine-protein kinase Fyn inhibitor | 0.155 0.125 DBMET00158 0.148 0.137 DBMET01351 | DBMET00158 | |
| 0.051 | 0.389 | 0.163 | Ca2+/calmodulin-dependent kinase II beta inhibitor | 0.163 0.112 DBMET01351 | DBMET01351 | |
| 0.039 | 0.378 | 0.093 | Transcription factor NF kappa B stimulant | 0.093 0.047 DBMET00157 | DBMET00157 | |
| 0.112 | 0.459 | 0.179 | 5 Hydroxytryptamine 3E antagonist | 0.17 0.136 DBMET00158 0.179 0.108 DBMET01351 | DBMET01351 | |
| 0.028 | 0.379 | 0.119 | Ca2+/calmodulin-dependent kinase II gamma inhibitor | 0.119 0.117 DBMET01351 | DBMET01351 | |
| 0.015 | 0.369 | 0.081 | Platelet activating factor alpha antagonist | 0.081 0.079 DBMET00158 | DBMET00158 | |
| 0.048 | 0.422 | 0.306 | Tumour necrosis factor alpha release inhibitor | 0.306 0.051 DBMET00157 | DBMET00157 | |
| 0.068 | 0.458 | 0.176 | Death-associated protein kinase 2 inhibitor | 0.15 0.107 DBMET00158 0.176 0.059 DBMET01351 | DBMET01351 | |
| 0.011 | 0.403 | 0.064 | HIV-1 reverse transcriptase inhibitor | 0.064 0.055 DBMET01351 | DBMET01351 | |
| 0.138 | 0.534 | 0.299 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.281 0.239 DBMET00158 0.299 0.214 DBMET01351 | DBMET01351 | |
| 0.055 | 0.466 | 0.152 | Ca2+/calmodulin-dependent kinase I alpha inhibitor | 0.152 0.142 DBMET01351 | DBMET01351 | |
| 0.046 | 0.476 | 0.235 | DNA synthesis inhibitor | 0.196 0.13 DBMET00158 0.235 0.078 DBMET01351 | DBMET01351 | |
| 0.031 | 0.481 | 0.061 | Prolactin release inhibitor | 0.061 0.049 DBMET01351 | DBMET01351 | |
| 0.048 | 0.499 | 0.204 | Angiogenesis inhibitor | 0.204 0.165 DBMET00158 | DBMET00158 | |
| 0.026 | 0.48 | 0.102 | MAP kinase kinase 7 inhibitor | 0.073 0.07 DBMET00158 0.102 0.012 DBMET01351 | DBMET01351 | |
| 0.012 | 0.475 | 0.049 | Antibiotic Aminoglycoside-like | 0.049 0.014 DBMET00157 | DBMET00157 | |
| 0.019 | 0.49 | 0.074 | Somatostatin 1 agonist | 0.074 0.059 DBMET01351 | DBMET01351 | |
| 0.053 | 0.564 | 0.257 | Immunomodulator | 0.257 0.109 DBMET00157 | DBMET00157 | |
| 0.042 | 0.587 | 0.509 | Antibacterial | 0.509 0.038 DBMET00157 0.242 0.185 DBMET01351 | DBMET00157 | |
| 0.049 | 0.613 | 0.131 | MAP kinase kinase 4 inhibitor | 0.131 0.11 DBMET01351 | DBMET01351 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |